Saturday, April 10, 2021 8:06:54 PM
Just reading over a few posts. Mostly the uninformed speakers. Im going to point out one obvious flaw im seeing people make here. Folks. Some of our best and most promising IP at Regen is not theory or concept. Our IP has a combined total of thousands of Lab hours. High-End Labs. Quality Matters! Not some Rinky Dink here today gone tomorrow labs. But At places like Cornell Medical! With Cornell Professors. With FDA clinical clearances. Ect.
This is not an off the ground start from 0 push here by any means folks. CROs like ChemDiv.com also were involved. Highly developed IP folks.
What happened?
We ran out of money to keep going. Simple as that. Then add a world Wide Pandemic that stopped all funding of anything not frontline covid-19 related...
Take a look around. Funded. And thats an understatement. Millions in funding. And CROs already lined up for Koos thru ONPH.
I bet we have revenue from our IP... this Year. Thats how far along some of this is.
And folks. One last thing. Look at all the buy out and buy your IP in the Biotech world happening. Hello? Show me a better value purchase for gilead then this. Which leads to Those super Vote Dividend class shares. That were step 2 in Koos return. Before even ONPH deal April 7. So obviously not for them IMO. Funny how the non-coverting share class specific to a buy out scenario were Above all these deals and funding and Financial Update(8k) in order of occurence... still have no explanation for those dividend shares... and that is a very serious potential. Life-changing perhaps.
Hello?
Anybody home?
Opportunity is Knocking.
Multiple dollars. In 2021. Promise.
And if you haven’t yet. 2 Must Read Articles:
https://microcapdaily.com/regen-biopharma-inc-otcmkts-rgbp-parabolic-run-on-kls-oncology-pharma-deal/131542/?amp&__twitter_impression=true
https://insiderfinancial.com/regen-biopharma-about-to-become-a-major-pharma-player/181241/amp/?__twitter_impression=true
This is not an off the ground start from 0 push here by any means folks. CROs like ChemDiv.com also were involved. Highly developed IP folks.
What happened?
We ran out of money to keep going. Simple as that. Then add a world Wide Pandemic that stopped all funding of anything not frontline covid-19 related...
Take a look around. Funded. And thats an understatement. Millions in funding. And CROs already lined up for Koos thru ONPH.
I bet we have revenue from our IP... this Year. Thats how far along some of this is.
And folks. One last thing. Look at all the buy out and buy your IP in the Biotech world happening. Hello? Show me a better value purchase for gilead then this. Which leads to Those super Vote Dividend class shares. That were step 2 in Koos return. Before even ONPH deal April 7. So obviously not for them IMO. Funny how the non-coverting share class specific to a buy out scenario were Above all these deals and funding and Financial Update(8k) in order of occurence... still have no explanation for those dividend shares... and that is a very serious potential. Life-changing perhaps.
Hello?
Anybody home?
Opportunity is Knocking.
Multiple dollars. In 2021. Promise.
And if you haven’t yet. 2 Must Read Articles:
https://microcapdaily.com/regen-biopharma-inc-otcmkts-rgbp-parabolic-run-on-kls-oncology-pharma-deal/131542/?amp&__twitter_impression=true
https://insiderfinancial.com/regen-biopharma-about-to-become-a-major-pharma-player/181241/amp/?__twitter_impression=true
Sometimes its Skil, Sometimes its Luc.
I’d rather have 1 genuine team follower then 100 look-a-likes.
Appreciate Member Marks!
ALL IMHO
Recent RGBP News
- Regen BioPharma Update on Orphan Drug Application for HemaXellerate Will Be Presented At Emerging Growth Conference on September 24, 2025 • GlobeNewswire Inc. • 09/23/2025 12:00:00 PM
- Regen BioPharma Prepares Response For FDA Regarding Its Orphan Drug Application for HemaXellerate • GlobeNewswire Inc. • 09/16/2025 12:00:00 PM
